This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As an Esthetician with 35 years of experience one of the questions I get asked most is, “How can I get rid of skin discoloration?” I get this from teens all the way up to seniors since discoloration affects most everyone. We all want our skin to look flawless without having to hide under makeup to get that even-toned look that we desire.
The U.S. Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This action follows the recent FDA approval of nemolizumabfor subcutaneous injection for the treatment of adults with prurigo nodularis in August 202
In its 2025 Beauty Trends Report, Spate predicted all of the trends it sees in beauty based on growing online searches. The beauty trends were organized into skin care, hair, makeup, bath/body and fragrance categories.
Intermittent fasting could slow hair growth, according to research in mice published in Cell Press. Mice subjected to intermittent fasting regimens showed improved metabolic health but slower hair regeneration compared to mice with 24/7 access to food. A similar process might occur in humans, based on a small clinical trial that the team also conducted, but its likely to be less severe since humans have a much slower metabolic rate and different hair growth patterns compared to mice, the study a
What if your snacks didnt just hit the spot but actually worked to transform your skin? At Enlightened Beauty, we believe that skincare goes beyond what you put on your faceits also about what you nourish your body with. The right foods can help your skin fight acne, calm inflammation, and maintain a natural glow. In this blog, were sharing snack ideas inspired by the Medical Mediums approach to healing from the inside out.
I was delighted to join Niki Wolfe on her fantastic podcast, Wellness for Life, to discuss a topic thats incredibly close to my heart: navigating the menopause transition. Menopause is a transformative stage of life, but it can also bring its fair share of challengesfatigue, hot flushes, and hormonal shifts being just a few of them. During our conversation, we explored practical strategies to tackle these issues head-on.
In case you missed it, this week we had news about the 308 nm excimer light and 2940 erbium laser for vitiligo, the new Diamond technique for the neck and dcollet, potential risk factors for developing CHE in China, and more.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting marketing authorization for nemolizumab (Nemluvio. Galderma) for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumabs approval for subcutaneous use for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic th
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content